| Date | Tue, Feb 28, 2023 1:00 pm – 2:00 pm | |
|---|---|---|
| Location | Webinar |
The Centers for Disease Control and Prevention (CDC) has detected an increase in extensively drug-resistant (XDR) Shigella infections (shigellosis) reported through national surveillance systems. XDR shigellosis is resistant to all generally recommended antibiotics in the United States, making it difficult to treat. XDR shigellosis is a serious public health threat: XDR Shigella bacteria have limited antimicrobial treatment options, are easily transmissible, and can spread antimicrobial resistance genes to other enteric bacteria. Clinicians should understand the nuances of testing and managing infections, especially when treating patients from populations at increased risk of drug-resistant shigellosis including: young children; gay, bisexual, and other men who have sex with men; people experiencing homelessness; international travelers; and people living with HIV.
During this COCA Call, subject matter experts from CDC, the Colorado Department of Public Health and Environment, and the UK Health Security Agency will provide updates on the current domestic and global epidemiology of XDR shigellosis, discuss its relevance for clinicians in the United States, describe infection presentation, explain the importance of having a detailed sexual and travel history, share approaches for clinical management, and review how clinicians should test and report shigellosis.
Free Continuing Education (CE) will be offered for this COCA Call.